#United States #Orlando #Hematology #Solu Therapeutics #STX-0712

Solu Therapeutics to Present at ASH Annual Meeting

Solu Therapeutics, a leader in innovative biotechnology aimed at combatting cancer and immune disorders, has revealed plans to present key results of a groundbreaking clinical trial for its promising therapy, STX-0712. This presentation is set to occur at the American Society of Hematology (ASH) Annual Meeting, running from December 6 to 9, 2025, in Orlando, Florida.

Overview of STX-0712

STX-0712 is classified as a CCR2-CyTAC™ (Chemokine Receptor Type 2 Cytotoxicity Targeting Chimera), designed specifically for tackling chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). These two blood cancers pose significant treatment challenges, especially in patients who are refractory or resistant to existing therapies. The upcoming presentation will showcase crucial insights from a Phase 1 open-label, multicenter study that evaluates the safety and efficacy of STX-0712.

Study Details

The ongoing trial aims to establish primary objectives, including safety, determination of dose-limiting toxicities, and the appropriate Phase 2 dosage for further research. Secondary objectives focus on profiling pharmacokinetics and pharmacodynamics, assessing tolerability, and showcasing any preliminary anti-tumor activity observed in participants.

Key elements of the study design will be highlighted, including:

• - Dose Escalation: Utilizing a Bayesian Optimal Interval approach to gradually elevate the dosage for optimal therapeutic impact.
• - Dose Expansion: Plans for expanding dosages to further understand the drug's effect across larger populations.
• - Exploratory Analyses: Assessing the depletion of CCR2+ cells, identifying relevant biomarkers, profiling immune cell responses, and analyzing patient-reported outcomes.

Importance of CCR2 in Treatment

STX-0712 targets the G-Protein Coupled Receptor CCR2, a receptor linked to the malignant monocytes significant in hematologic cancers. By effectively eliminating these malignant cells, STX-0712 represents a promising avenue in cancer therapy, focusing on precision and efficacy.

Presentation Information

The session will feature Dr. Guillermo Montalban Bravo from the Department of Leukemia at the esteemed MD Anderson Cancer Center, who will be presenting the findings:

• - Abstract Title: A First-in-Human Study of STX-0712, a CCR2+ Cytotoxicity Targeting Chimera (CyTAC™), in Patients with CMML and AML.
• - Date: December 7, 2025
• - Time: 6:00 PM - 8:00 PM EST
• - Location: Room OCCC-West Halls B3-B4
• - Session: 637. Myelodysplastic Syndromes Clinical and Epidemiological Poster II
• - Abstract Number: 14421

About Solu Therapeutics

Solu Therapeutics is deeply committed to pioneering cutting-edge therapies aimed at eradicating disease-driving cells. Their proprietary platforms, including the CyTAC™ and TicTAC™ technologies, are geared towards developing novel treatments that bridge the therapeutic potential of both small molecules and biologics. The company's mission centers on advancing the treatment landscape for various cancers and immune-related conditions, one transformative therapy at a time.

As anticipation builds for the findings to be shared at the ASH Annual Meeting, the oncology community eagerly awaits insight into how STX-0712 could revolutionize treatment pathways for patients afflicted by challenging forms of leukemia.